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Abstract
Background—Cadmium (Cd) and lead (Pb) are widespread environmental contaminants that are 
known nephrotoxins. However, their nephrotoxic effects at low-environmental exposure levels are 
debated.
Objective—We examined the association of blood Pb (B-Pb), blood Cd (B-Cd), urinary Pb (U-
Pb) and urinary Cd (U-Cd) with estimated glomerular filtration rate (eGFR) and urinary albumin 
(ALB).
Methods—We used multivariate linear regression to analyze the association between B-Pb, B-
Cd, U-Pb, and U-Cd with eGFR and ALB in adult participants (≥20 years of age) in NHANES 
2007–2012. The dataset was limited to NHANES individuals with both blood and urinary metal 
measurements.
Results—We found a statistically significant inverse association between eGFR and B-Cd and 
statistically significant positive associations between eGFR and both U-Cd and U-Pb, as well as 
statistically significant associations between ALB and the 3rd and 4th quartiles of U-Cd.
Conclusions—The inverse association between eGFR and B-Cd, in conjunction with positive 
associations between eGFR and ALB with U-Cd, suggest that U-Cd measurement at low levels of 
exposure may result from changes in renal excretion of Cd due to kidney function and protein 
excretion. However, renal effects such as hyperfiltration from Cd-mediated kidney damage or 
creatinine-specific Cd effects cannot be excluded with this cross-sectional design.
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Chronic kidney disease (CKD)is a leading cause of death in the United States (Levey et al., 
2009). The estimated prevalence of CKD among people in the United States 20 years of age 
and older is greater than 10% (Zhang and Rothenbacker 2008). High blood pressure 
(McCarley and Burrows-Hudson 2006) and diabetes (Baumgarten and Gehr 2011; Collins et 
al., 2013) are known risk factors for CKD; furthermore, exposure to chemical substances can 
also play a role in the development of this disease (Franchini et al., 2005; Gingsberg 2012; 
Soderland et al., 2010).
Cadmium (Cd) and lead (Pb) are two environmental pollutants that exhibit nephrotoxic 
activity, frequently evidenced by decreased GFR and increased levels of albumin loss in 
urine (ALB) (ATSDR 2007, 2012). Cadmium is a widespread industrial and environmental 
pollutant, with food and tobacco being the primary sources of exposure in the United States 
(ATSDR, 2012). Lead is widespread in the environment and exposure can occur through 
contact with air, tobacco smoke, household dust, soil, water, food, and commercial products 
(ATSDR, 2007). Cadmium and Pb nephrotoxicity effects are dose-dependent (Bernard, 
2008). Studies of workers with chronic Cd exposure (Chaumont et al., 2012; Jarup et al., 
1998) have estimated that urinary Cd (U-Cd) in the range of 4–10μg/g creatinine is 
associated with increased microproteinuria (non-albumin proteins passing from the blood 
through the glomeruli into the urinary tract), and the U.S. Occupational Safety and Health 
Administration considers 3 μg Cd/g of creatinine as the safety standard for U-Cd (OSHA, 
1993).
Studies over the past decade have reported a statistically significant association of low-level 
environmental Pb and/or Cd exposure with renal dysfunction in the general population using 
both cross-sectional (Navas-Acien et al., 2009; Ferraro et al., 2010) and prospective cohort 
(Kim et al., 1996; Yu et al. 2004) study designs.
Recently, however, the potential nephrotoxic effects of low-level Cd exposure have been 
called into question. Weaver et al. (2011a, b) reported an association of higher U-Cd with 
increased eGFR; further studies have confirmed this association, describing a pattern of 
increased B-Cd and decreased U-Cd associated with decreased eGFR, as well as positive 
associations between U-Cd and ALB and select other urinary proteins (Akerstrom et al., 
2013; Chaumont et al., 2012). These findings suggest that the reported associations between 
low-level metal exposure and perturbations in renal activity are not a simple causal 
relationship, but represent a more complex interplay between Cd effects on the kidney and 
the renal function’s effects on the accumulation and excretion of Cd. Based on analyses of 
the types of proteins excreted and non-creatinine based markers of kidney function, several 
studies have suggested that the patterns of association between eGFR and U-Cd and B-Cd 
may be a consequence of reverse causality, with kidney function driving measured levels of 
B-Cd and U-Cd, rather than an effect of Cd on the kidneys (Akerstrom et al., 2013; 
Chaumont et al., 2012; Evans and Elinder, 2011; Haddam et al., 2011).
Lead nephrotoxicity is characterized by proximal tubular nephropathy, glomerular sclerosis, 
and interstitial fibrosis (Diamond 2005). Studies of rats fed with a continuous high dose of 
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lead (5000 ppm) showed a statistically significant increased eGFR compared to controls 
after 3 months, followed by a decreased eGFR at 6, 9 and 12 months. The decreased eGFR 
reached statistical significance relative to the control only after 12 months of exposure. 
Histologically, the kidneys presented proximal tubule inclusion bodies, interstitial fibrosis, 
tubular atrophy, and focal glomerular sclerosis (Khalil-Manesh et al., 1992). A study from 
the same group on rats fed with a continuous low dose of lead (100 ppm) showed a 
statistically significantly increased eGFR at 3 months compared to controls, but the eGFR at 
6, 9, and 12 months was comparable to controls (Kalil-Manesh et al., 1993). No 
morphological changes were observed in the kidney.
To weigh in on these recent hypotheses, we investigated the associations between Cd and Pb 
blood and urine levels with renal dysfunction in NHANES 2007–2012. We assessed whether 
the association of blood and urine Pb- and particularly Cd-levels with eGFR and albuminuria 
is consistent with the patterns described by Akerstrom et al. (2013) and others, which have 
called into question the direct causal relationship of low level metal exposure leading to 
reduced kidney function. To facilitate the comparison of the potential associations between 
renal outcomes with blood metals and urine metals, we restricted our analyses to adult 
participants (≥20 years of age) who had both urinary and blood measures of Pb and Cd. Our 
analyses confirm findings from recent studies of a positive relationship between U-Cd and 
eGFR, associated with a concurrent inverse relationship between B-Cd and eGFR at low 
levels of Cd exposure using current NHANES data. Furthermore, we report a previously 
unidentified positive relationship between U-Pb and eGFR.
METHODS
Study Population
NHANES is a cross-sectional, nationally representative survey of the non-institutionalized 
civilian population of the United States conducted by the National Center for Health 
Statistics (NCHS), Centers for Disease Control and Prevention (CDC) (NCHS 2008). 
Beginning in 1999, the survey was conducted continuously and released in 2-year cycles. 
For our study we merged the publicly available files for NHANES cycles 2007–2008, 2009–
2010, and 2011–2012 using the NCHS recommendations (NCHS 2013a). The survey 
employs a multistage stratified probability sample based on selected counties, blocks, 
households, and persons within households. The NHANES 2007–2010 and 2011–2012 
study protocols are approved by the National Center for Health Statistics Institutional 
Review Board (Protocol #2005–2006 and Protocol #2011–17, respectively http://
www.cdc.gov/nchs/nhanes/irba98.htm).
In the 2007–2008, 2009–2010, and 2011–2012 data sets, urinary concentrations of cadmium 
and lead were measured in a randomly selected one-third subsample. For our analysis, we 
included all participants who had measurements for U-Cd, U-Pb, B-Cd, and B-Pb. Pregnant 
and breastfeeding women were excluded.
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Whole blood Pb and Cd concentrations were determined using inductively coupled plasma 
mass spectrometry. Cd and Pb in spot urine specimens were measured by inductively 
coupled plasma-mass spectrometry using a multi-element analytical technique. Levels below 
the limit of detection were entered as the limit of detection divided by the square root of two. 
Blood Cd, B-Pb, U-Cd, and U-Pb were categorized as weighted quartiles based on the 
distribution of blood and urine metal levels among the study population, resulting in 
approximately the same number of participants within each quartile. A total of 973 of the 
4875 participants had B-Cd values below the limit of detection (LOD 2007–2012: 0.20 μg/l), 
so these were considered the referent lowest Cd quartile. The LOD for B-PB was 0.25 μg/dl, 
for U-PB was 0.1 μg/l for NHANES 2007–2010 and 0.08 μg/l for NHANES 2011–2102, for 
U-Cd was 0.042 μg/l for NHANES 2007–2010 and 0.056 μg/l for NHANES 2011–2012. 
The percent of participants at or above the LOD were: 99.61 for B-Pb, 96.55 for U-Pb and 
91.87 for U-Cd,
Renal Outcomes
Urinary albumin (ALB) was measured in spot urine samples by solid-phase fluorescence 
immunoassay. The lower limit of detection for the assay is 0.3 μg/mL. Urinary creatinine 
was measured by the modified kinetic Jaffé method. The ratio of albumin to creatinine 
(ACR) was reported in milligrams per gram and categorized by using 30 mg/g as a cutoff; 
albuminuria is considered to be present when ACR is greater than 30 mg/g (Levey et al., 
2003). ACR was not normally distributed, thus it was natural log-transformed and the results 
were re-transformed by exponentiation of the β coefficients and presented as percent 
differences estimated by comparing each of the upper three quartiles to the lowest quartile 
using the formula 100*(eβ −1).
Estimated glomerular filtration rate (eGFR) was calculated by using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation 1 :eGFR (mL/minute/1.73 m2) = 
141 × min(SCr/κ, 1)α × max(SCr/κ, 1)−1.209 × 0.993Age × 1.018 if female × 1.159 if non-
Hispanic- black, where SCr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 
−0.329 for females and −0.411 for males, min indicates the minimum of SCr/κ or 1, and 
max indicates the maximum of SCr/κ or 1. Analyses using the Modification of Diet in Renal 
Disease Study formula for the eGFR held the same significant associations (data not shown). 
Chronic Kidney Disease was defined as eGFR < 60 mL/minute/1.73m2 (Levey et al., 2009).
Covariates
We obtained information about age (continuous, years), sex, race/ethnicity (non-Hispanic 
White, non-Hispanic Black, Mexican-American, Other Hispanic, or Other), and education 
(less than high school, completed high school, or more than high school) from the household 
interview. Alcohol consumption (amount consumed per week, categorized as no alcohol, 1–
4 drinks/week, of >4 drinks/week) and self-reported smoking status (current smoker, former 
smoker, or never smoker) were obtained from the physical examination and associated 
questionnaire. Body mass index (BMI) was obtained from the physical examination and 
calculated by dividing measured weight in kilograms by measured height in meters squared. 
Body weight status was classified as normal/underweight, overweight, and obese with BMI 
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measures of <25, 25–29.9, and ≥30, respectively. Diabetes status was defined as glycated 
hemoglobin (A1C) ≥ 6.5%, or self-reported current use of insulin or oral hypoglycemic 
agents. Hypertension was defined as self-reported current use of an antihypertensive 
medication, or systolic BP ≥140 mmHg, or diastolic BP ≥90 mmHg.The self- reported 
weak/failing kidney was obtained from the Kidney Conditions questionnaire.
Serum creatinine was measured by the modified kinetic method of Jaffe. Urinary creatinine 
was determined using a Jaffe rate reaction measured with a CX3 analyzer. To account for 
variation in dilution in spot urinary samples, urinary creatinine was entered into the models 
as an independent variable, as suggested by previous studies (Barr et al. 2005; Ikeda et al. 
2003). Because the distribution of this variable was not normal, we log-transformed it in 
analyses. Serum cotinine, a biomarker of environmental tobacco smoke, was categorized as 
weighted quartile based on the distribution among the study population. In our analyses we 
did not exclude participants with self-reported diagnosis of kidney cancer. However, 
analyses including, also, as independent variable the self-report diagnosis of kidney cancer 
(obtained from the medical questionnaire), did not change the the results of our primary 
analyses (data not shown).
Statistical analysis
Sample weights were used for analyses to account for the complex sampling design and 
non-response of NHANES. Weights for combined NHANES survey cycles were calculated 
according to NHANES guidelines (NCHS 2008b). Because urinary heavy metals are 
measured only in a subsample of the participants, specific urinary metal subset sample 
weights were used in the models with U-Pb and U-Cd. All other analyses used the exam 
sample weights. We estimated sampling errors using the Taylor series linearized method. We 
used multivariate linear regression to calculate adjusted β-coefficients, using models without 
(Model 1) and with (Model 2) inclusion of B-Cd (for Pb analyses) and B-Pb (for Cd 
analyses). We looked at the interaction terms between the metal concentrations (ln-
transformed) and the covariates included in the models. The only statistically significant 
interaction was found with age, which supports the known association between age and 
decreasing kidney function.
We also assessed the collinearity between blood and urine metal measures using Pearson 
correlation coefficients and multicollinearity diagnostic statistics (tolerance and variance 
inflation factors [VIF]). A value of VIF≥10 often indicates multicollinearity. No covariates 
were multicollinear with each other. There was a moderate correlation between blood and 
urine measures as indicated by the Spearman correlation coefficients (r = 0.56, p<0.001 for 
B-Pb and U-Pb;r=0.27, p<0.0001 for B-Pb and U-Cd; r = 0.46, p<0.001 for B-Cd and U-Cd; 
and r=0.17. p<0.0001 for B-Cd and U-Pb).
SAS 9.3 (SAS Institute, Cary, NC) was used for all statistical analyses and SAS-Callable 
SUDAAN 10 (Research Triangle Institute, Research Triangle Park, NC) was used to account 
for the NHANES complex sample design. P-values were presented at the significance level 
< 0.05. Statistical tests for linear trends were conducted by modeling quartiles as an ordinal 
variable using integer values and p-value for trend based on Wald test.
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The geometric mean age for the 4,875 study participants was 44.1 years, and there was an 
approximately equal representation of men and women. The geometric mean B-Cd 
concentrations was 0.35 μg/L and the geometric mean B-Pb level was 1.23 μg/dL. The 
geometric mean U-Cd concentrations was 0.22μg/L and the geometric mean U-Pb level was 
0.45 μg/L. 418 individuals had eGFR <60 mL/minute/1.73 m2 (weighted percentage 6.13%) 
a filtration rate indicative of CKD, and 584 individuals (weighted percentage 8.79%) 
presented with urinary albumin/creatinine ratio (ACR) ≥30mg/g, a ratio indicating potential 
albuminuria. Table 1 presents additional characteristics of the study populations.
Table 2 presents the mean change in eGFR with quartile levels of B-Cd, B-Pb, U-Cd, and U-
Pb, with the β values representing the change in eGFR (mL/minute/1.73 m2) comparing the 
three highest quartiles to their respective referent lowest quartile. The two highest B-Cd 
quartiles (Q3 and Q4) showed statistically significant inverse associations with eGFR levels, 
with a statistically significant increase in the strength of association moving from lowest 
quartile (Q1) to Q4 indicating evidence of dose-response (Models 1 and 2).
Blood Pb Q3 and Q4 were inversely associated with eGFR (Model 1), with a similarly 
significant increase in the strength of association moving from Q1 to Q4; when B-Cd was 
added (model 2), B-Pb Q4 was still significantly associated, but the statistically significant 
trend moving from Q1 to Q4 was lost. Conversely, U-Cd and U-Pb Q3 and Q4 showed 
statistically significant positive associations with eGFR (Models 1 and 2). There was a 
significant increase in the strength of association moving from Q1 to Q4 for U-Pb in models 
1 and 2 and for U-Cd in model 1, with a marginally significant association in U-Cd model 2 
(p = 0.06).
Table 3 presents the percent change in ALB with quartile levels of B-Cd, B-Pb, U-Cd and U-
Pb. Overall, we found that U-Cd Q2, Q3 and Q4 were associated with statistically 
significantly higher excretion of ALB, both with (model 2) and without (model 1) inclusion 
of B-Pb in the model, with evidence of a dose-response relationship (p trend <0.001No 
significant associations were found between B-Cd, U-Cd, or U-Pb and ALB in any of the 
models. Analyses without urinary creatinine as independent variable confirm the similar 
statistic association of U-Cd with ALB (Supplemental Table 1)
As complementary analyses, we used log natural-transformed urinary and blood Cd and Pb 
levels. These analyses showed similar results to those using weighted quartiles in all 
participants (Table 4).
DISCUSSION
In our study, we found that with increased eGFR, there is increased U-Cd and U-Pb 
excretion. Conversely, eGFR was inversely associated with increased B-Cd and B-Pb. To our 
knowledge, this is the first study to demonstrate both the positive associations of U-Cd and 
U-Pb and the inverse associations of B-Cd and B-Pb with eGFR using the most recent 
NHANES data, a larger and more nationally representative dataset than that which has been 
used by previous studies describing these interesting associations.
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Our findings are also consistent with studies conducted on previous NHANES cycles. 
Navas-Acien et al., (2009) investigated associations of B-Cd and B-Pb with CKD in 14,778 
adults (≥20 years of age) using NHANES 1999–2006. They found that the fully adjusted 
highest quartiles of both B-Cd and B-Pb were statistically significantly associated with 
higher odds of CKD (OR=1.32, 95% CI: 1.04, 1.68 and OR=1.56, 95% CI: 1.17, 2.08, 
respectively). Additionally, they found higher odds ratios for ACR in the third and fourth 
quartiles of B-Cd (OR=1.32, 95% CI: 1.07, 1.64 and OR=1.92, 95% CI: 1.53, 2.43, 
respectively) but no association with B-Pb (Navas-Acien et al., 2009). Ferraro et al., (2010), 
in addition to studying the association between B-Cd and CKD in a subset of participants in 
the same NHANES dataset (1999–2006) that had both U-Cd and B-Cd measurements, 
further investigated the role of U-Cd in renal outcomes. Using B-Cd as a dichotomous 
variable (≤1 μg/L and >1 μg/L), they confirmed the positive association between B-Cd and 
CKD (OR=1.48, 95% CI: 1.01, 2.17) as well as with ACR (OR=1.41 95% CI: 1.10, 1.82). 
When investigating U-Cd, they found an inverse, though not statistically significant, 
association with CKD in individuals with U-Cd levels > 1μg/g creatinine compared to those 
with U-Cd ≤ 1μg/g creatinine (OR=0.70, 95% CI: 0.47, 1.04) (Ferraro et al., 2010). 
Therefore, our results of positive associations between U-Cd and inverse associations of B-
Cd and B-Pb with eGFR are consistent with the previous findings related to CKD, as 
reduced eGFR is an indicator of CKD.
While the cross-sectional nature of our study design prevents definitive assessment of the 
causal directionality underlying any associations described, the positive relationship between 
eGFR and U-Cd, and the inverse association between eGFR and B-Cd may be consistent 
with the hypothesis of reverse causality put forward by Chaumon et al., (2012) and 
Akerstrom et al., (2013), among others. Reverse causality predicts that reduced eGFR will 
decrease the total filtration of the chemical substances and consequently lead to decreased 
levels in the urine and increased levels in the blood.
Furthermore, the association we observed between U-Cd and ALB may point to a co-
excretion function of the kidney, as suggested in recent studies (Akerstrom et al., 2013; 
Chaumont et al., 2012; Evans and Elinder 2011; Haddam et al., 2011). Haddam et al., (2011) 
found that urinary albumin did not correlate with B-Cd, but was consistently associated with 
U-Cd through a relationship that was unaffected by age, smoking, or diuresis. However, the 
authors do note that co-excretion of retinol-binding protein (RBP) may be influencing the 
association between albumin and U-Cd (Haddam et al., 2011). Chaumont et al. (2012) in a 
cross-sectional study of 736 adolescents reported associations between B-Cd, B-Pb, U-Cd, 
and U-Pb with concentrations of urinary albumin and the low-molecular weight (LMW) 
proteins RBP and β2-microglobulin (β2m). They argued that the overall evidence favors a 
non-causal association originating from the co-excretion of Cd- or Pb-binding proteins with 
LMW proteins; because of evidence that Cd and Pb primarily circulate while bound to 
LMW proteins, the observed associations at low exposures might simply reflect the inter-
individual variations in the renal uptake of proteins sharing the same affinity for tubular 
binding sites (Chaumont et al., 2012). Two mechanisms leading to protein-metal co-
excretion were proposed: 1) the physiological variation in fractional uptake of proteins by 
proximal tubules when ALB is low, which may account for the non-threshold linear 
relationships between U-RBP and U-Cd and between U-β2m and U-Pb found in the 
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adolescents with no increase of ALB; or 2) competitive inhibition of LMW protein 
reabsorption by ALB, which is the only protein whose concentration can markedly increase 
in tubular fluid in the absence of renal failure (Chaumon et al., 2012). Akerstrom et al., 
(2013) in a study among 30 non-smoking healthy adults found U-Cd excretion was 
positively associated with ALB excretion as well as urinary LMW protein α-1-
microglobulin (A1M). They also found significant positive associations of urinary flow with 
excretion of U-Cd, ALB, and U-A1M, suggesting that the association in individuals with 
low-level exposure to Cd is unlikely caused by Cd toxicity but instead results from normal 
variation in renal function, including changes in urinary flow that may influence the urinary 
excretion of both Cd and proteins in the same direction.
Other plausible hypotheses are also supported by our findings. The first, suggested by Weber 
et al. (2011b), is that low-level Cd and Pb exposure can lead to glomerular hyperfiltration, 
which can be indicative of kidney damage. While prospective studies on the nephrotoxic 
effects of low-level Cd exposure are lacking, several studies conducted among the general 
population reported an association of higher B-Pb with lower glomerular filtration rate using 
both cross-sectional and prospective designs (Fadrowski et al 2010; Kim et al., 1996; 
Muntner et al., 2003; Staeesen et al., 1990, 1992; Yu et al., 2004). In our study, we describe 
a similar association between B-Pb and eGFR. However, we believe that the positive 
association we found is not necessarily reflective of the same causal relationship described 
in prospective studies, which establishes the nephrotoxic potential of low-level Pb exposure, 
because of the differences in Pb levels between our study and the others. While still 
classified as “low-level exposure,” Yu et al. (2004) and Kim et al. (1996) both report mean 
B-Pb levels between 2.5 and 8 times greater than those described in this study.
Another alternative hypothesis was proposed by Weaver et al. (2011a) in a study 
investigating low-level U-Cd and eGFR in 712 lead workers. Multivariate linear analyses 
showed that higher ln-transformed U-Cd was associated with lower serum creatinine, higher 
calculated creatinine clearance, and higher eGFR (β coefficient for eGFR=8.7 mL/min/
1.73m2, 95% CI: 5.4, 12.1). In a follow-up analysis of the same population, Weaver et al., 
(2011b) confirmed their previous findings between ln-transformed U-Cd and higher 
creatinine-based eGFR. In this follow-up study, they also examined the association between 
U-Cd and serum cystatin C measures to try and elucidate a potential mechanism for their 
previous finding of an inverse association. They found that U-Cd was not associated with 
cystatin C outcomes, thus suggesting that the association seen between U-Cd and eGFR may 
be a “creatinine-specific mechanism rather than a kidney function mechanism” (Weaver et 
al., 2011b). In our analyses, we could not confirm Weaver et al.,’s suggestion of a creatinine-
based mechanism for the inverse association between U-Cd and renal outcomes because 
cystatin C measurement is not available in NHANES 2007–2012.
This study used the NHANES 2007–2012 dataset, a large, national survey whose findings 
are generalizable to the U.S. adult non-institutionalized population. Although there are 
strengths to this study including its large sample-size and random sampling, there are 
important limitations to note. The cross-sectional design is unable to definitively assess 
questions of causality (and reverse causality), although it can be beneficial in refining and 
supporting hypotheses. While our findings are consistent with the hypothesis of reverse 
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causation, the relationship of blood and urinary Cd concentrations at low levels of exposure 
with kidney dysfunction is a complex one that cannot be fully assessed using cross-sectional 
data alone. Further mechanistic studies using animal models and human prospective cohort 
research are necessary to assess this relationship.
The use of blood and urine Cd and Pb levels as markers for exposure is further complicated 
by the deposition of these metals within the body; Cd selectively accumulates in the renal 
cortex, which has over 50% of the body burden of cadmium (ATSDR 2012), whereas Pb 
accumulates in bone, with bone Pb levels accounting for over 90% of the total body burden 
(ATSDR 2007). Therefore, the levels of B-Cd and blood and urine Pb may not be the best 
indications of total body burden. Furthermore, the use of a single spot urine sample for U-Cd 
and U-Pb is a limitation in our analyses. The pattern observed in the association between U-
Pb and eGFR should also be assessed with the caveat that a single-spot U-Pb measure is not 
a very reliable assay. Urinary Pb measures are reflective of Pb that has diffused from the 
plasma and excreted through the kidneys, and these measures can be useful when collected 
for long-term biomonitoring. A single spot urine sample, as assessed in this study, may be 
unreliable because it can be subjected to biological variations. However, the use of a single 
spot measure may be acceptable when there is a creatinine excretion correction factor 
included in analyses (Barbosa et al. 2005). Therefore, while the use of a single-spot U-Pb 
measure may be limited, we have tried to lessen this impact by including urinary creatinine 
in the analysis. Finally, although we controlled for many of the known factors associated 
with renal outcomes, other genetic and environmental factors may have influenced our 
findings.
CONCLUSION
Despite the continuous decrease in blood Cd and Pb levels in the U.S. population, we 
confirmed the previously reported associations between B-Cd and B-Pb levels with adverse 
renal outcomes. However, the inverse direction of the associations of U-Cd and U-Pb may 
suggest that, at this low-level exposure, the results may also be attributed to a reverse 
causation action: a decreased glomerular filtration will result in a build-up of Cd and Pb in 
the blood, with a contemporarily decrease of urinary excretion of Cd and Pb. If these 
associations are due to reverse causation, they may be important both from a clinical and 
public health prospective because subjects with decreased glomerular filtration may retain 
the compounds, which may potentially exacerbate their toxic effects in the kidney and other 
organs.
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Table 1
Sample size (N) and weighted characteristics of adult participants (≥20 years of age) with blood lead, blood 
cadmium, urinary lead and urinary cadmium in NHANES 2007–2012.
n Weighted
Urinary Cadmium (μg/L), GM (SE) 4875 0.22 (0.00)
Urinary Cadmium (μg/L), Mean (Lower 95%, Upper 95%) 0.35 (0.34, 0.37)
Urinary Lead (μg/L), GM (SE) 4875 0.45 (0.01)
Urinary Lead (μg/L), Mean (Lower 95%, Upper 95%) 0.70 (0.64, 0.76)
Blood Cadmium (μg/L), GM (SE) 4871 0.35 (0.01)
Blood Cadmium (μg/L), Mean (Lower 95%, Upper 95%) 0.51 (0.49, 0.52)
Blood Lead (μg/dL), GM (SE) 4871 1.23 (0.02)
Blood Lead (μg/dL), Mean (Lower 95%, Upper 95%) 1.58 (1.49, 1.67)
Age (Years), GM (SE) 4875 44.10 (0.49)
BMI(kg/m2), GM (SE) 4875 27.88 (0.13)
Serum Cotinine (ng/mL), GM (SE) 4875 0.31 (0.03)
Serum Creatinine (mg/dL), GM (SE) 4875 0.85 (0.00)
eGFR (mL/minute/1.73 m2) GM (SE) 4875 91.95 (0.58)
Urinary Creatinine (mg/dL), GM (SE) 4874 92.16 (1.44)
Urinary Albumin 4874 7.42 (0.16)
Urinary Albumin/Urinary Creatinine Ratio 4874 8.05 (0.16)
Sex
Men 2481 49.53 (0.67)
Women 2394 50.47 (0.67)
CKD
Yes, % (SE) 418 6.13 (0.46)
No, % (SE) 4457 93.87 (0.46)
ACR
Yes, % (SE) 584 8.79 (0.51)
No, % (SE) 4290 91.21 (0.51)
Hypertension*
Yes, % (SE) 1831 32.08 (0.85)
No, % (SE) 3044 67.92 (0.85)
Diabetes**
Yes, % (SE) 556 8.03 (0.48)
No, % (SE) 4319 91.97 (0.48)
Body Weight
Underweight/Normal weight,, % (SE) 1462 32.31 (1.09)
Overweight, % (SE) 1615 33.26 (1.17)
Obese, % (SE) 1798 34.43 (1.03)
Self-reported Smoking Status
Current Smoker, % (SE) 1031 21.01 (0.84)
Former Smoker, % (SE) 1205 24.87 (0.96)
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n Weighted
Never Smoked, % (SE) 2639 54.12 (1.15)
Self-reported Alcohol Consumption
No Alcohol, % (SE) 1588 27.08 (1.04)
1–4 drinks per week, % (SE) 2889 64.65 (1.34)
>4 drinks per week, % (SE) 398 8.26 (0.64)
Education Status
Less than High School % (SE) 1347 18.23 (1.08)
Completed High School % (SE) 1092 22.42 (1.07)
More than High School % (SE) 2436 59.35 (1.60)
Race/ethnicity
 White (Non-Hispanic) % (SE) 2203 69.30 (2.08)
 Non-Hispanic Black % (SE) 990 10.86 (1.083)
 Mexican-American % (SE) 744 7.87 (1.08)
 Other Hispanic % (SE) 533 5.75 (0.85)
 Other % (SE) 405 6.22 (0.66)
Weak/Failing Kidney
Yes, % (SE) 128 2.31 (0.35
No, % (SE) 4738 97.69 (0.35)
Hypertension was defined as self-reported current use of an antihypertensive medication, or systolic BP ≥140 mmHg, or diastolic BP ≥90 mmHg.
**
Diabetes status was defined as glycated hemoglobin (A1C) > 6.5% or self-reported current use of insulin or oral hypoglycemic agents
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Table 2
Adjusted β-coefficient (95% CIs) of eGFR (mL/minute/1.73 m2) by blood cadmium, blood lead, urinary 
cadmium, and urinary lead.
Model 1a Model 2b
B-Cd Quartilec
B-Cd Q1 0.00 0.00
B-Cd Q2 −1.08 (−2.96, 0.80) −0.91 (−2.75, 0.93)
B-Cd Q3 −2.44 (−4.79, −0.09) −2.11 (−4.40, 0.18)
B-Cd Q4 −4.29 (−6.48, −2.10) −3.66 (−5.81, −1.50)
p trend 0.01 0.03
B-Pb Quartilec
B-Pb Q1 0.00 0.00
B-Pb Q2 −1.35 (−3.10, 0.41) −1.17 (−2.91, 0.57)
B-Pb Q3 −2.02 (−4.00, −0.05) −1.62 (−3.60, 0.36)
B-Pb Q4 −3.27 (−5.39, −1.16) −2.67 (−4.78, −0.56)
p trend 0.02 0.08
U-Cd Quartilec
U-Cd Q1 0.00 0.00
U-Cd Q2 1.01 (−0.80, 2.83) 1.36 (−0.45, 3.17)
U-Cd Q3 1.92 (0.20, 3.64) 2.43 (0.71, 4.15)
U-Cd Q4 2.69 (0.34, 5.03) 3.55 (1.22, 5.89)
p trend 0.12 0.03
U-Pb Quartilec
U-Pb Q1 0.00 0.00
U-Pb Q2 3.72 (2.11, 5.33) 3.99 (2.40, 5.59)
U-Pb Q3 5.59 (3.77, 7.41) 5.96 (4.13, 7.78)
U-Pb Q4 7.73 (5.71, 9.76) 8.51 (6.46, 10.55)
p trend <0.01 <0.01
a
Model 1: adjusted for age, race/ethnicity, sex, diabetes, alcohol intake, education, smoking status, body weight, hypertension, weak/failing kidney, 
serum cotinine, and ln urinary creatinine (for the urinary models only)
b
Models 2: included the variables in model 1 and blood lead (ln μg/dL) for blood cadmium and urinary cadmium models; and blood cadmium (ln 
μg/dL) for blood lead and urinary lead models
c
Blood Cadmium Quartiles (μg/L): Q1: <0.20; Q2: 0.20–0.31; Q3: 0.32–0.57; Q4: >0.57; Blood Lead Quartiles (μg/dL): Q1: ≤0.79; Q2: 0.80–1.20; 
Q3: 1.21–1.82; Q4: >1.82; Urinary Cadmium Quartiles (μg/L): Q1: <0.111; Q2: 0.111–0.216; Q3: 0.217–0.421; Q4: >0.421; Urinary Lead 
Quartiles (μg/L): Q1: ≤0.25; Q2: 0.26–0.46; Q3: 0.47–0.79; Q4: >0.79.
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Table 3
Percent differences (95% CIs) in ALB by blood cadmium, blood lead, urinary cadmium, and urinary lead.
Model 1a Model 2b
B-Cd Quartilec
B-Cd Q1 referent referent
B-Cd Q2 −2.27 (−11.57, 7.90) −2.57 (−11.84, 7.68)
B-Cd Q3 1.51 (−7.23, 11.18) 0.90 (−7.69, 10.41)
B-Cd Q4 10.30 (−3.44, 25.86) 8.98 (−4.88, 24.86)
p trend 0.31 0.38
B-Pb Quartilec
B-Pb Q1 referent referent
B-Pb Q2 −3.05 (−13.06, 8.33) −4.02 (−13.76, 6.93)
B-Pb Q3 −7.23 (−17.30, 4.08) −9.24 (−19.43, 2.22)
B-Pb Q4 9.86 (−2.96, 24.61) 6.29 (−6.39, 20.80)
p trend 0.02 0.02
U-Cd Quartilec
U-Cd Q1 referent referent
U-Cd Q2 18.06 (6.18, 31.26) 17.82 (6.08, 31.00)
U-Cd Q3 32.05 (20.08, 45.21) 31.52 (19.48, 44.77)
U-Cd Q4 44.34 (26.74, 64.38) 43.48 (26.24, 63.07)
p trend <0.001 <0.001
U-Pb Quartilec
U-Pb Q1 referent referent
U-Pb Q2 6.82 (−5.07, 20.20) 5.97 (−5.73, 19.12)
U-Pb Q3 2.63 (−8.52, 15.14) 1.61 (−9.34, 13.88)
U-Pb Q4 14.00 (−0.10, 30.21) 11.29 (−2.08, 26.49)
p trend 0.09 0.17
a
Model 1: adjusted for age, race/ethnicity, sex, diabetes, alcohol intake, education, smoking status, body weight, hypertension, weak/failing kidney, 
serum cotinine, and ln urinary creatinine (for the urinary models only)
b
Model 2: included the variables in model 1 and blood lead (ln μg/dL) for blood cadmium model; blood cadmium (ln μg/dL) for blood lead model; 
or blood lead (ln μg/dL) and blood cadmium (ln μg/dL) for the urinary lead or urinary cadmium quartiles.
c
Blood Cadmium Quartiles (μg/L): Q1: <0.20; Q2: 0.20–0.31; Q3: 0.32–0.57; Q4: >0.57; Blood Lead Quartiles (μg/dL): Q1: ≤0.79; Q2: 0.80–1.20; 
Q3: 1.21–1.82; Q4: >1.82; Urinary Cadmium Quartiles (μg/L): Q1: <0.111; Q2: 0.111–0.216; Q3: 0.217–0.421; Q4: >0.421; Urinary Lead 
Quartiles (μg/L): Q1: ≤0.25; Q2: 0.26–0.46; Q3: 0.47–0.79; Q4: >0.79.
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